{"id":"https://openalex.org/W3095657159","doi":"https://doi.org/10.1182/blood-2020-143088","title":"A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies","display_name":"A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3095657159","doi":"https://doi.org/10.1182/blood-2020-143088","mag":"3095657159"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-143088","doi":"https://doi.org/10.1182/blood-2020-143088","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-143088","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101838284","display_name":"Jae H. Park","orcid":"https://orcid.org/0000-0002-2903-5130","observed_orcids":["https://orcid.org/0000-0002-2903-5130","https://orcid.org/0009-0003-2678-9513"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jae H. Park","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036831073","display_name":"Isabelle Rivi\u00e8re","orcid":"https://orcid.org/0000-0002-7363-3963","observed_orcids":["https://orcid.org/0000-0002-7363-3963"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabelle Riviere","raw_affiliation_strings":["Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034388262","display_name":"Devanjan S. Sikder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Devanjan S. Sikder","raw_affiliation_strings":["Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109051698","display_name":"Vladimir P. Bermudez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vladimir P. Bermudez","raw_affiliation_strings":["Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062885345","display_name":"Brigitte S\u00e9n\u00e9chal","orcid":"https://orcid.org/0000-0003-2467-5152","observed_orcids":["https://orcid.org/0000-0003-2467-5152"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brigitte Senechal","raw_affiliation_strings":["Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101691044","display_name":"Xiuyan Wang","orcid":"https://orcid.org/0000-0002-0552-2559","observed_orcids":["https://orcid.org/0000-0002-0552-2559"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiuyan Wang","raw_affiliation_strings":["Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036960496","display_name":"Thomas H. Auchincloss","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas H. Auchincloss","raw_affiliation_strings":["Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033055418","display_name":"Claudia Diamonte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Claudia Diamonte","raw_affiliation_strings":["Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077473098","display_name":"Elizabeth F. Halton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Halton","raw_affiliation_strings":["Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052659722","display_name":"Maria Lia Palomba","orcid":"https://orcid.org/0000-0001-5099-9156","observed_orcids":["https://orcid.org/0000-0001-5099-9156"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Lia Palomba","raw_affiliation_strings":["Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065556543","display_name":"Renier J. Brentjens","orcid":"https://orcid.org/0000-0002-3364-5388","observed_orcids":["https://orcid.org/0000-0002-3364-5388"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Renier J. Brentjens","raw_affiliation_strings":["Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059625599","display_name":"Michel Sadelain","orcid":"https://orcid.org/0000-0002-9031-8025","observed_orcids":["https://orcid.org/0000-0002-9031-8025"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michel Sadelain","raw_affiliation_strings":["Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York City, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York City, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1334819555"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.2723,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.56153262,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"43","last_page":"44"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd19-car-t-cells","display_name":"CD19 CAR T cells","score":0.8830000162124634},{"id":"https://openalex.org/keywords/relapsed-or-refractory-b-cell-malignancies","display_name":"relapsed or refractory B-cell malignancies","score":0.9129999876022339},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9369999766349792},{"id":"https://openalex.org/keywords/primary-mediastinal-large-b-cell-lymphoma","display_name":"primary mediastinal B-cell lymphoma","score":0.8899999856948853},{"id":"https://openalex.org/keywords/high-grade-b-cell-lymphoma","display_name":"high-grade B-cell lymphoma","score":0.8180000185966492},{"id":"https://openalex.org/keywords/car-t-cell-persistence","display_name":"CAR T cell persistence","score":0.859000027179718},{"id":"https://openalex.org/keywords/complete-response-rate","display_name":"complete response rate","score":0.4339999854564667}],"concepts":[{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.6567078828811646},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.6410169005393982},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5529928207397461},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4879438281059265},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4601505398750305},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.457421213388443},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45700323581695557},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.44151073694229126},{"id":"https://openalex.org/C148125776","wikidata":"https://www.wikidata.org/wiki/Q1622348","display_name":"CD28","level":4,"score":0.417949914932251},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.30672311782836914},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2323717474937439},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.217806875705719},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1618497371673584},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-143088","doi":"https://doi.org/10.1182/blood-2020-143088","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-143088","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310120140","https://openalex.org/W348274993","https://openalex.org/W2561107731","https://openalex.org/W2600730797","https://openalex.org/W109146070","https://openalex.org/W2906492823","https://openalex.org/W3183792933","https://openalex.org/W2302451205","https://openalex.org/W4417022378","https://openalex.org/W2556211489"],"abstract_inverted_index":{"Background:":[0],"Autologous":[1],"CAR":[2,53,75,99,103,121,128,175,194,211,226,304,372,462,532,721],"T":[3,88,129,176,187,195,212,373,533,546,722],"cell":[4,89,130,188,284,504,534,547,723],"therapy":[5,326,535,717],"targeting":[6],"the":[7,50,66,110,145,151,158,207,221,340,376,394,402,429,448,455,470,480],"B-cell":[8,23,266],"specific":[9],"surface":[10],"antigen":[11],"CD19":[12,98,303,313,531],"has":[13,513],"demonstrated":[14,143],"favorable":[15,163,540],"clinical":[16,258],"responses":[17],"in":[18,73,220,262,463,516],"relapsed":[19],"or":[20,581],"refractory":[21],"(R/B)":[22],"lymphomas":[24],"(BCL).":[25],"However,":[26],"despite":[27],"40-60%":[28],"initial":[29],"complete":[30],"response":[31],"(CR)":[32],"rates,":[33],"only":[34],"a":[35,45,60,74,96,162,224,238,253,334,367,643],"subset":[36],"of":[37,52,68,109,154,165,173,182,209,223,234,260,312,358,361,370,447,460,469,485,492,502,508,529,579],"patients":[38,263,379,436],"experience":[39],"durable":[40],"remissions,":[41],"and":[42,58,70,91,93,167,178,228,232,248,295,327,363,385,420,441,458,476,478,495,506,539,710],"there":[43],"is":[44,252,314,400,450,472],"need":[46],"to":[47,136,338,391,406,452,473,527,719],"further":[48,205,453],"improve":[49,206],"efficacy":[51,494,538],"therapies":[54,305],"by":[55,106,157,366],"preventing":[56],"relapse":[57],"attaining":[59],"deeper":[61],"CR.":[62],"We":[63],"hypothesized":[64],"that":[65,144],"redundancy":[67],"CD28":[69],"CD3V":[71],"signaling":[72],"design":[76,227,337],"incorporating":[77],"all":[78],"3":[79,111,359],"CD3Vimmunoreceptor":[80],"tyrosine-based":[81],"activation":[82,104,155],"motifs":[83],"(ITAMs)":[84],"might":[85],"foster":[86],"counterproductive":[87],"differentiation":[90],"exhaustion,":[92],"therefore":[94],"created":[95],"new":[97],"construct":[100],"with":[101,132,192,264,301,380,410,437,536,543],"calibrated":[102],"potential":[105],"mutating":[107],"2":[108,397,433,483],"ITAMs,":[112],"termed":[113,244],"1XX.":[114],"In":[115,375],"systemic":[116,324],"ALL":[117],"mouse":[118],"models,":[119],"19-28z1XX":[120,159,225,235],"induced":[122],"effective":[123,180],"tumor":[124],"eradication":[125],"at":[126,185,268],"low":[127],"doses":[131,189],"improved":[133,530],"survival":[134],"compared":[135],"conventional":[137],"19-28z":[138,193],"CAR.":[139],"Further":[140],"preclinical":[141],"studies":[142],"enhanced":[146,537],"therapeutic":[147],"benefit":[148],"resulted":[149],"from":[150],"reduced":[152],"strength":[153],"mediated":[156],"CAR,":[160],"achieving":[161],"balance":[164],"effector":[166],"memory":[168],"functions,":[169],"thereby":[170],"enhancing":[171],"persistence":[172,208],"functional":[174,210],"cells":[177,196],"promoting":[179],"elimination":[181],"CD19+":[183],"leukemia":[184,298],"lower":[186,544],"than":[190],"needed":[191],"(Feucht":[197],"J":[198],"et":[199],"al.":[200],"Nat":[201],"Med":[202],"2019).":[203],"To":[204],"cells,":[213],"we":[214],"screened":[215],"different":[216],"humanized":[217,240],"CD19-directed":[218],"scFv":[219,241],"context":[222],"proved":[229],"high":[230,287,382,417],"specificity":[231],"functionality":[233],"CARs":[236],"containing":[237],"novel":[239],"T2":[242],"-":[243],"19(T2)28z1XX.":[245,486],"Study":[246],"Design":[247],"Methods:":[249],"This":[250],"study":[251,332,403,524],"single":[254,368],"center":[255],"Phase":[256,482],"I":[257],"trial":[259,449,471,512],"19(T2)28z1XX":[261,371,461,720],"R/R":[265,280],"malignancies":[267],"Memorial":[269],"Sloan":[270],"Kettering":[271],"Cancer":[272],"Center":[273],"(NCT04464200).":[274],"Key":[275,316,487],"disease":[276],"eligibility":[277,426],"criteria":[278,318,427],"include":[279,319,435,490,500],"diffuse":[281],"large":[282],"B":[283,503],"lymphoma":[285],"(DLBCL),":[286],"grade":[288,383,418],"BCL,":[289,292,384,439],"primary":[290,386,421,467],"mediastinal":[291,387,422],"indolent":[293,438],"BCL":[294,388,419,423],"chronic":[296],"lymphocytic":[297],"(CLL).":[299],"Patients":[300,352],"prior":[302,718],"are":[306,347,389,521],"eligible":[307,390],"as":[308,310,323,428,715],"long":[309],"expression":[311],"confirmed.":[315],"exclusion":[317],"ongoing":[320],"immunosuppression":[321],"such":[322],"GvHD":[325],"active":[328],"CNS":[329],"disease.":[330],"The":[331,444,466,511,519],"uses":[333],"3+3":[335],"dose-escalation":[336,377,430],"identify":[339],"maximum":[341],"tolerated":[342],"dose":[343,398,407,484],"for":[344],"BCL.":[345],"There":[346],"5":[348],"planned":[349],"flat-dose":[350],"levels.":[351],"will":[353,404,434,525,712],"receive":[354],"conditioning":[355,716],"chemotherapy":[356],"consisting":[357],"days":[360],"fludarabine":[362,711],"cyclophosphamide":[364],"followed":[365],"infusion":[369],"cells.":[374],"phase,":[378],"DLBCL,":[381,416],"participate.":[392],"Once":[393],"recommended":[395,481],"phase":[396,409],"(RP2D)":[399],"determined,":[401],"open":[405],"expansion":[408],"two":[411],"cohorts.":[412],"Cohort":[413,432],"1":[414],"includes":[415],"(i.e.":[424],"same":[425],"phase).":[431],"CLL,":[440],"Richter's":[442],"transformation.":[443],"dose-expansion":[445],"part":[446],"designed":[451],"characterize":[454],"safety,":[456],"efficacy,":[457],"pharmacokinetics":[459],"multiple":[464],"indications.":[465],"objective":[468],"evaluate":[474],"safety":[475],"tolerability":[477],"determine":[479],"secondary":[488],"objectives":[489,499],"evaluation":[491],"19(T2)28z1XX's":[493],"cellular":[496],"kinetics.":[497],"Exploratory":[498],"assessment":[501],"aplasia,":[505],"analysis":[507],"serum":[509],"cytokines.":[510],"begun":[514],"enrollment":[515],"August":[517],"2020.":[518],"investigators":[520],"hopeful":[522],"this":[523],"lead":[526],"development":[528],"toxicity":[541],"profiles":[542],"infused":[545],"dose.":[548],"Disclosures":[549],"Park:":[550],"AstraZeneca:":[551],"Consultancy;":[552,570,572,604,606,666],"Servier:":[553],"Consultancy,":[554,558,562,566,589,593,612,621],"Research":[555,559,563,567,586,590,594,597,601,617,630,633,636,639,648,651,662,681,688,705],"Funding;":[556,560,564,568,587,591,595,598,602,618,631,634,640,649,652,663,682,689],"Autolus:":[557],"Amgen:":[561],"Takeda:":[565,632,701],"Novartis:":[569,653],"Minverva:":[571],"Artiva:":[573],"Membership":[574],"on":[575],"an":[576],"entity's":[577],"Board":[578],"Directors":[580],"advisory":[582],"committees;":[583],"Fate":[584,683],"Therapeutics:":[585,600,626,665,684],"Kite:":[588],"Incyte:":[592],"Genentech/Roche:":[596],"Juno":[599,625,641,667],"GSK:":[603],"Intellia:":[605],"Allogene:":[607],"Consultancy.":[608],"Riviere:Fate":[609],"Therapeutics":[610,668],"Inc.:":[611],"Other:":[613,622,627,691],"Ownership":[614,623,628],"interest":[615],",":[616,693],"FloDesign":[619],"Sonics:":[620],"interest;":[624],"interest,":[629],"Atara:":[635],"Funding.":[637,706],"Palomba:Genentech:":[638],"Therapeutics,":[642],"Bristol-Meyers":[644],"Squibb":[645,672],"Company:":[646],"Honoraria,":[647],"Regeneron:":[650],"Honoraria;":[654,656,658],"Merck:":[655],"Celgene:":[657],"Pharmacyclics:":[659],"Honoraria.":[660],"Brentjens:BMS:":[661],"Gracell":[664],"(a":[669],"Bristol":[670],"Myers":[671],"company):":[673],"Patents":[674,678,685,694,698,702],"&":[675,679,686,695,699,703],"Royalties.":[676],"Sadelain:Atara:":[677],"Royalties,":[680,687,704],"Minerva:":[690],"Biotechnologies":[692],"Royalties;":[696,700],"Mnemo:":[697],"OffLabel":[707],"Disclosure:":[708],"Cyclophosphamide":[709],"be":[713],"used":[714],"administration.":[724]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2020-11-09T00:00:00"}